Helus Pharma Inc. (NASDAQ:HELP) shares declined 21% on Monday after the pharmaceutical company reported topline results from its Phase 3 APPROACH clinical trial, which met its primary endpoint evaluating HLP003 as an adjunctive treatment for major depressive disorder (MDD).
The company reported a statistically significant 7.6-point placebo-adjusted improvement from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 6, with a p-value of less than 0.0001.
The results also showed a statistically significant treatment effect as early as Day 2, with a 5.0-point placebo-adjusted reduction in MADRS scores (p=0.0013).
Despite the reported clinical findings, Helus Pharma shares fell 21% during Monday’s trading session.
The APPROACH trial enrolled 222 participants diagnosed with moderate to severe major depressive disorder.
All participants continued receiving stable doses of their existing antidepressant medications throughout the study, allowing investigators to assess HLP003 as an additional treatment.
At baseline, the average MADRS total score was 32.7 among patients assigned to HLP003, compared with 33.8 in the placebo group.
The MADRS is a clinical assessment scale used to measure the severity of depressive symptoms, with lower scores indicating fewer symptoms.
At Week 6, HLP003 achieved a 7.6-point greater reduction from baseline than placebo, meeting the study’s primary efficacy endpoint.
The company also reported a statistically significant treatment difference at Day 2, indicating that an effect was observed during the early stages of the study.
Helus Pharma reported that the treatment difference remained statistically significant at Week 12, meeting a key secondary endpoint.
At that point, patients receiving HLP003 demonstrated a 7.0-point placebo-adjusted improvement from baseline on the MADRS scale, with a p-value of less than 0.0001.
The findings indicate that the difference in depressive symptom scores between the treatment and placebo groups was maintained through the 12-week assessment period.
The company also disclosed response rates at multiple time points during the study.
At Day 2, the response rate was 50.0% among HLP003 recipients, compared with 23.6% in the placebo group.
At Week 6, response rates were 56.3% for HLP003 and 28.2% for placebo.
By Week 12, the corresponding rates were 45.5% and 19.1%, respectively.
These results provide additional information about the proportion of participants meeting the study’s criteria for treatment response.
The APPROACH study also evaluated remission rates, which measure the proportion of patients whose depressive symptoms decline to a level meeting the trial’s remission criteria.
At Day 2, remission was reported in 39.3% of patients receiving HLP003, compared with 15.5% of those receiving placebo.
At Week 6, remission rates reached 50.9% in the HLP003 group and 18.2% in the placebo group.
At Week 12, the corresponding figures were 40.2% and 15.5%.
The reported remission rates were higher in the HLP003 group at each of the three assessment points.
The company presented these findings alongside the primary and secondary MADRS results as part of its topline clinical trial announcement.
Helus Pharma said HLP003 was generally well tolerated during the APPROACH study.
Most adverse events reported during treatment were classified as mild or moderate in severity and were transient.
However, three treatment-related serious adverse events occurred among participants receiving HLP003.
The company stated that no new safety signals were identified during the trial.
The topline announcement did not provide additional details about the nature of the three serious adverse events.
The safety findings will form part of the overall evaluation of HLP003 as the company continues its Phase 3 clinical development programme.
APPROACH represents the first of three clinical studies within Helus Pharma’s PARADIGM Phase 3 development programme for HLP003.
The company expects to report topline findings from the EMBRACE trial, another study within the programme, during the fourth quarter of 2027.
The additional clinical results will provide further information about the treatment’s efficacy and safety in patients with major depressive disorder.
Although APPROACH met its primary endpoint and demonstrated statistically significant differences from placebo across several assessments, HLP003 remains under clinical investigation.
The company’s next reported development milestone is the anticipated release of EMBRACE topline results in late 2027.
Helus Pharma stock price
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-16 | |
| Nov-15 | |
| Nov-03 | |
| Oct-27 | |
| Oct-26 | |
| Oct-21 | |
| Oct-15 | |
| Oct-08 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite